Correlation Between Oxidative Stress Status and COVID-19 Severity

Correlation Between Oxidative Stress Markers and COVID-19 Severity Index

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04375137

Enrollment

Registered

2020-05-05

Start date

2020-04-20

Completion date

2022-05-30

Last updated

2023-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative Stress

Brief summary

During the new COVID-19 pandemic physicians all over the world have faced different challenges .Oxidative stress is a probable cause of multi organ failure in this setting which never has been evaluated in COVID-19 infection to the best of knowledge.Present study aimed to evaluate oxidative stress marker and redox system status in different COVID-19 patients regarding the severity of involvement.

Detailed description

Oxidative stress is a probable cause of multi organ failure in this setting which never has been evaluated in COVID-19 infection to the best of knowledge.Present study aimed to evaluate oxidative stress marker and redox system status in different COVID-19 patients regarding the severity of involvement. Demographic and lab data of 60 COVID-19 confirmed positive cases gathered .These patients divided in to two arms: 1- severe COVID-19 which were intubated or admitted in intensive care unit due to severe hypoxia 2- non-severe COVID-19 patients which were not hypoxic and admitted in ward with no need to invasive oxygenation. All patients had positive RT-PCR positive nasopharyngeal swab results for COVID-19 or Lung CT scan compatible with COVID-19. Malondialdehyde(MDA) , Biopterin, Neopterin, SOD, Glutathione levels would be checked by ELISA tests and compared between these two groups and healthy controls.

Interventions

DIAGNOSTIC_TESTOxidative Stress ELISA Kit

Checking oxidative stress markers and redox system status

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* more than 18 years old * positive RT-PCR COVID-19 * compatible lung CT with COVID-19

Exclusion criteria

* not signing informed consent * using antioxidants * using statins

Design outcomes

Primary

Measure	Time frame	Description
MDA concentration	2 weeks	MDA x 2 ULN in severe COVID

Secondary

Measure	Time frame	Description
Biopterin concentration	2 weeks	Difference between severe and controls
Neopterin rate of increase	2 weeks	Difference between severe and controls

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026